Silexion Therapeutics Corp. is a biotech company developing RNA interference therapies for KRAS-driven cancers. They announced a public offering of 1,500,000 ordinary shares, series A warrants for 1,500,000 shares, and series B warrants for 1,500,000 shares at a price of $4.00 per share. The series A warrants can be exercised immediately and expire in five years, while the series B warrants expire in twelve months. The offering is expected to close on or around September 12, 2025, pending customary closing conditions.